2018
DOI: 10.24060/2076-3093-2018-8-1-52-56
|View full text |Cite
|
Sign up to set email alerts
|

Low Level of Antithrombin Iii as a Warning Sign for Developing Thrombotic Complications in Surgical Patients

Abstract: SummaryIntroduction. Pulmonary embolism (PE), being the most severe embolic complication, is characterised by low predictability, high mortality and incapacitation rates as well as a correspondingly high economic cost of therapy and aftercare. In this connection, the main purpose of our work is to find a warning for PE development in non-cardiosurgical patients that have undergone intensive therapy under conditions of general surgical ICU, among the indicators of the haemostasis system.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 15 publications
0
1
0
1
Order By: Relevance
“…Независимо от вида оперативного лечения помимо коррекции нутритивного статуса всем пациентам проводилась профилактика тромбоэмболических и инфекционных осложнений по показаниям [8,9], мониторинг центральной гемодинамики [11] и биохимических маркеров повреждения печени и нутритивной недостаточности [12].…”
Section: материалы и методыunclassified
“…Независимо от вида оперативного лечения помимо коррекции нутритивного статуса всем пациентам проводилась профилактика тромбоэмболических и инфекционных осложнений по показаниям [8,9], мониторинг центральной гемодинамики [11] и биохимических маркеров повреждения печени и нутритивной недостаточности [12].…”
Section: материалы и методыunclassified
“…Examples include products based on fibrin or thrombin for local hemostasis in abdominal surgery or traumatology [1], proton-pump inhibitors to prevent recurrence of bleeding from the gastrointestinal tract [2], antifibrinolytic funds, and desmopressin for the system hemostasis [3]. However, drugs to stop bleeding, traditionally used in medical practice, are not always effective to lead to the effective reduction of blood loss which is dangerous due to the development of hemorrhagic shock, dilutional coagulopathy, or thrombosis and thromboembolic complications [4]. Overview of clinical recommendations shows that among synthetic systemic hemostatic drugs, the highly proved efficacy was confirmed only for tranexamic acid, aminocaproic acid, and etamsylate [5,6].…”
Section: Introductionmentioning
confidence: 99%